WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Thank you for another great WorkBoat Show! We hope to see everyone back in New Orleans December 2–4, 2026. Save the date!

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

839.51 -5.41 (-0.64%)
Streaming Delayed Price Updated: 11:30 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
From argenx SE
Via GlobeNewswire
News headline image
Key Takeaways From argenx Analyst Ratings ↗
 
Via Benzinga
News headline image
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
News headline image
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? ↗
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart... 
Via Benzinga
News headline image
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results ↗
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued 
Via Benzinga
News headline image
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
News headline image
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies ↗
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG. 
Via Benzinga
News headline image
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights. 
Via Benzinga
News headline image
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
News headline image
argenx Highlights 2024 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
News headline image
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes ↗
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus... 
Via Benzinga
News headline image
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off ↗
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.